All figures in Canadian dollars ($) unless otherwise specified
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - March 2, 2026) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced results of the quarter ended December 31, 2025.
Summary Financials - Third Quarter Ended December 31, 2025
| Nine months ended | ||
| (000's) | December 31, 2025 | December 31, 2024 |
| Revenue | $ 1,818 | $ 3,240 |
| Adjusted EBITDA* (Loss) | $ 293 | $ (2,295) |
| Net Loss | $ (2,279) | $ (6,721) |
| Net Loss per Share | $ (0.01) | $ (0.04) |
*Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization). The term Adjusted EBITDA does not have any standardized meaning under IFRS Accounting Standards. Therefore, it may not be comparable to similar measures presented by other companies.
- For further detailed information and analysis, please see the financial statements and management's discussion and analysis for the period ending December 31, 2025, as posted at sedarplus.ca and pharmacielo.com.
Management Commentary
Marc Lustig, Chairman and CEO of PharmaCielo, commented, "The third quarter marked an important turning point for PharmaCielo. We have re-established a solid foundation from which to rebuild momentum and create long-term shareholder value. The revenue for the nine-month period reflects a deliberate transition in our commercial strategy. The significant improvement in Adjusted EBITDA demonstrates the operational discipline and cost controls implemented over the past year. Our focus has been on rightsizing the organization, improving production efficiencies in Colombia, and prioritizing higher margin export opportunities. Our near-term objectives are clear: drive consistent export volumes, strengthen our relationships with strategic international partners, and secure repeat purchase agreements that support predictable revenue growth."
Annual General and Special Meeting
The Company's most recent Annual General Meeting ("AGM") was held on February 20, 2024. The upcoming AGM will be held on April 2, 2026, at 11:00 a.m. Eastern Time at 82 Richmond Street East, Toronto, Ontario, M5C 1P1. The record date for determining shareholders entitled to vote at the AGM was set as February 23, 2026. Shareholders will be asked to elect directors, appoint auditors, and consider other customary business.
About PharmaCielo
PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable cultivating, processing and supply of all natural, pharmaceutical-grade medicinal and commercial dried cannabis flower and cannabis products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing center located in Rionegro, Colombia.
For further information
Ian Atacan, Chief Financial Officer
i.atacan@pharmacielo.com
Media and Investor Inquires:
investors@pharmacielo.com
Forward-Looking Statements
This news release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects", "is expected", "intends", "anticipates", "believes", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be completed or achieved. Forward-looking statements in this news release include, without limitation, statements regarding potential financing transactions, and the possible conversion of debentures.
The forward-looking statements in this news release are necessarily based on assumptions, including assumptions with respect to PharmaCielo's ability to obtain necessary approvals for the issuance of the debenture units.
Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including changes to PharmaCielo's development plans, the failure to obtain and maintain all necessary regulatory approvals relating to the export of cannabinoid products and the import of these products into other countries, TSX Venture Exchange approval, the inability to export or distribute commercial products through sales channels as anticipated due to economic or operational circumstances, risks associated with operating in Colombia, fluctuation of the market price for the Company's products, risks associated with global economic and political instability or other developments, risks related to retention of key Company personnel, currency exchange risk, competition in PharmaCielo's market and other risks discussed or referred to under the heading "Risk Factors" in PharmaCielo's Annual Information Form for the financial year ended December 31, 2019, which is available at www.sedarplus.ca. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285827
Source: PharmaCielo Ltd.
